Nuggehally R. Srinivas
Research Subjects
Research Interests
Nuggehally R. Srinivas has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Ramesh Mullangi
Integrated Product Development, Dr Reddy's Laboratories Ltd, Bachupalli, Hyderabad, India
2 shared publicationsP. Ahlawat
Global Drug Development, ClinTec (India) International Pvt. Ltd, Bangalore, India
1 shared publicationShrutidevi Agrawal
Global Drug Development, ClinTec (India) International Pvt. Ltd, 3rd Floor, A Wing, Divyasree Chambers, Langford Road, Bangalore 560 025, India
1 shared publication
Latest Publications
- 10 March 2009
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (6) , 674-675
Applicability of LC/MS/MS assay for 6‐methoxy‐2‐napthylacetic acid to support the bioequivalence study of nabumetone—comments on the research work of Patel et al. (2008)
- 10 March 2009
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (6) , 674-675
Applicability of LC/MS/MS assay for 6‐methoxy‐2‐napthylacetic acid to support the bioequivalence study of nabumetone—comments on the research work of Patel et al. (2008)
- 10 March 2009
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (6) , 672-673
Novel 6‐hydroxy chroman‐based derivatization reagent for HPLC‐EC: challenges of ‘unsuspected’ chirality
- 10 March 2009
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (6) , 672-673
Novel 6‐hydroxy chroman‐based derivatization reagent for HPLC‐EC: challenges of ‘unsuspected’ chirality
- 2 March 2009
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (4) , 447-449
Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?
- 2 March 2009
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (4) , 447-449
Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?
- 1 January 2009
- Published by Bentham Science Publishers Ltd. in Current Clinical Pharmacology
- Vol. 4 (1) , 67-70
Structurally Modified ‘Dietary Flavonoids’: Are these Viable Drug Candidates for Chemoprevention?
The field of chemoprevention continues to be a heavily researched area since a few decades now. Whereas, the dietary intake of flavonoids occur via daily intakes of fruits, vegetables, herbal preparations, beverages etc, it appears that the active ingredients(s) contained in these dietary sources may not reach the required plasma and/or tissue concentrations in vivo to produce the desired pharmacological response expected of these agents. Akin to the common problems of druggability encountered often times in drug discovery/development scenario, low bioavailability of flavonoids have been attributed to: lack of stability, excessive metabolism, permeability problems, lack of site specificity in distribution, rapid elimination etc. The scope of the review is to assess and put into perspectives salient features of some of the recently reported work on dietary flavonoids including the methylated compounds that showed improved drug-like properties in context with the required features for the lead optimization program rendering a clinical candidate. In addition, it aims to provide some perspectives into the present day considerations for early drug development such as healthy subjects versus cancer patients, single agent versus combination potential with other cancer therapeutics, selection of a cancer indication, potential for drug-drug interaction etc. Although there has been an unabated use of ‘dietary flavonoids’ with tall order claims for chemoprevention, it may be extremely challenging to confirm it in a clinical setting. Overall, it appears prudent to develop a comprehensive prospective strategy for clinical development and regulatory approval.
- 1 January 2009
- Published by Bentham Science Publishers Ltd. in Current Clinical Pharmacology
- Vol. 4 (1) , 67-70
Structurally Modified ‘Dietary Flavonoids’: Are these Viable Drug Candidates for Chemoprevention?
The field of chemoprevention continues to be a heavily researched area since a few decades now. Whereas, the dietary intake of flavonoids occur via daily intakes of fruits, vegetables, herbal preparations, beverages etc, it appears that the active ingredients(s) contained in these dietary sources may not reach the required plasma and/or tissue concentrations in vivo to produce the desired pharmacological response expected of these agents. Akin to the common problems of druggability encountered often times in drug discovery/development scenario, low bioavailability of flavonoids have been attributed to: lack of stability, excessive metabolism, permeability problems, lack of site specificity in distribution, rapid elimination etc. The scope of the review is to assess and put into perspectives salient features of some of the recently reported work on dietary flavonoids including the methylated compounds that showed improved drug-like properties in context with the required features for the lead optimization program rendering a clinical candidate. In addition, it aims to provide some perspectives into the present day considerations for early drug development such as healthy subjects versus cancer patients, single agent versus combination potential with other cancer therapeutics, selection of a cancer indication, potential for drug-drug interaction etc. Although there has been an unabated use of ‘dietary flavonoids’ with tall order claims for chemoprevention, it may be extremely challenging to confirm it in a clinical setting. Overall, it appears prudent to develop a comprehensive prospective strategy for clinical development and regulatory approval.
- 19 December 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (5) , 451-454
Dodging matrix effects in liquid chromatography tandem mass spectrometric assays—compilation of key learnings and perspectives
Triple quad liquid chromatography mass spectrometric assays (LC/MS/MS) have revolutionized the analysis of drug(s)/metabolite(s) with exceptional speed, sensitivity and selectivity features. From inception to date, several new and innovative features have been regularly proposed by researchers to further enhance the value in the applicability of this analytical tool. However, owing to such compressed run times and scanty sample preparation procedures, LC/MS/MS assays that are not fully optimized generally have issues of matrix effects, where ionization potential is either suppressed or enhanced due to the presence of other materials (endogenous/exogenous) in the matrix. By definition, even co‐medications, isomeric or isobaric impurities, and drug excipients used in dosing solutions could also potentially contribute to matrix effects. This article captures some of the interesting work carried out by researchers to understand and handle matrix effects. Additionally, it provides perspectives to effectively deal with matrix effects. Copyright © 2008 John Wiley & Sons, Ltd.
- 19 December 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (5) , 451-454
Dodging matrix effects in liquid chromatography tandem mass spectrometric assays—compilation of key learnings and perspectives
Triple quad liquid chromatography mass spectrometric assays (LC/MS/MS) have revolutionized the analysis of drug(s)/metabolite(s) with exceptional speed, sensitivity and selectivity features. From inception to date, several new and innovative features have been regularly proposed by researchers to further enhance the value in the applicability of this analytical tool. However, owing to such compressed run times and scanty sample preparation procedures, LC/MS/MS assays that are not fully optimized generally have issues of matrix effects, where ionization potential is either suppressed or enhanced due to the presence of other materials (endogenous/exogenous) in the matrix. By definition, even co‐medications, isomeric or isobaric impurities, and drug excipients used in dosing solutions could also potentially contribute to matrix effects. This article captures some of the interesting work carried out by researchers to understand and handle matrix effects. Additionally, it provides perspectives to effectively deal with matrix effects. Copyright © 2008 John Wiley & Sons, Ltd.
- 15 November 2008
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 65 (3) , 321-322
Hyperthermic intraperitoneal perfusion chemotherapy—views on the observed variability in oxaliplatin pharmacokinetics
- 15 November 2008
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 65 (3) , 321-322
Hyperthermic intraperitoneal perfusion chemotherapy—views on the observed variability in oxaliplatin pharmacokinetics
- 4 November 2008
- Published by Taylor & Francis in Xenobiotica
- Vol. 38 (11) , 1377-1385
Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data
As a class, camptothecin analogues via market entry of topotecan and irinotecan, have shown promise for the treatment of various solid tumours. Topotecan, in particular, was chosen as the substrate for allometric scaling and prediction of human parameter values for both total clearance (CL) and volume of distribution (Vss). The availability of published data in mouse, rat, dog, and monkey paved the way for interspecies scaling via allometry. Although it appeared that at a minimum mouse, rat, and dog would reasonably fit in a three-species allometry scale-up, the inclusion of monkey data enabled a better prediction of the human parameter values for total topotecan–e.g., CL: allometric equation: 1.5234W0.7865; predicted value = 43.04 l h−1: observed CL = 24–53 l h−1; Vss: allometric equation: 1.1939W1.0208; predicted value = 91.29 litres: observed Vss = 66–146 litres. The proximity of the allometric exponent values of CL (0.7885) and Vss (1.0208) to the suggested values of 0.75 and 1.00 was not only encouraging, but also confirmed the applicability of interspecies scaling approach for topotecan. The data suggest that allometric scaling approaches with suitable correction factors could potentially be used to predict the human pharmacokinetics of novel CPT analogues prospectively.
- 4 November 2008
- Published by Taylor & Francis in Xenobiotica
- Vol. 38 (11) , 1377-1385
Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data
As a class, camptothecin analogues via market entry of topotecan and irinotecan, have shown promise for the treatment of various solid tumours. Topotecan, in particular, was chosen as the substrate for allometric scaling and prediction of human parameter values for both total clearance (CL) and volume of distribution (Vss). The availability of published data in mouse, rat, dog, and monkey paved the way for interspecies scaling via allometry. Although it appeared that at a minimum mouse, rat, and dog would reasonably fit in a three-species allometry scale-up, the inclusion of monkey data enabled a better prediction of the human parameter values for total topotecan–e.g., CL: allometric equation: 1.5234W0.7865; predicted value = 43.04 l h−1: observed CL = 24–53 l h−1; Vss: allometric equation: 1.1939W1.0208; predicted value = 91.29 litres: observed Vss = 66–146 litres. The proximity of the allometric exponent values of CL (0.7885) and Vss (1.0208) to the suggested values of 0.75 and 1.00 was not only encouraging, but also confirmed the applicability of interspecies scaling approach for topotecan. The data suggest that allometric scaling approaches with suitable correction factors could potentially be used to predict the human pharmacokinetics of novel CPT analogues prospectively.
- 20 October 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (1) , 26-41
Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug–drug interaction studies
Clopidogrel, owing to its excellent inhibitory property of platelet aggregation, is used to reduce the cardiovascular risks in patients with multiple co‐morbid conditions such as stroke, myocardial infarction and atherosclerosis. The current review focuses distinctly on three aspects: (a) an in‐depth coverage on the bioanalytical methods for the quantification of clopidogrel and its inactive carboxylic acid metabolite as well as the active metabolite in pre‐clinical and clinical samples; (b) an overview of the pharmacokinetic/pharmacodynamic aspects of clopidogrel; and (c) enumerating the key findings from drug–drug interaction studies of clopidogrel with various co‐substrates such as lanzoprazole, fluvastatin, atorvastatin, pravastatin, digoxin, ketoconazole, donezepil and theophylline. Copyright © 2008 John Wiley & Sons, Ltd.
- 20 October 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (1) , 26-41
Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug–drug interaction studies
Clopidogrel, owing to its excellent inhibitory property of platelet aggregation, is used to reduce the cardiovascular risks in patients with multiple co‐morbid conditions such as stroke, myocardial infarction and atherosclerosis. The current review focuses distinctly on three aspects: (a) an in‐depth coverage on the bioanalytical methods for the quantification of clopidogrel and its inactive carboxylic acid metabolite as well as the active metabolite in pre‐clinical and clinical samples; (b) an overview of the pharmacokinetic/pharmacodynamic aspects of clopidogrel; and (c) enumerating the key findings from drug–drug interaction studies of clopidogrel with various co‐substrates such as lanzoprazole, fluvastatin, atorvastatin, pravastatin, digoxin, ketoconazole, donezepil and theophylline. Copyright © 2008 John Wiley & Sons, Ltd.
- 24 September 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (1) , 3-25
Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives
The use of saliva for measuring xenobiotic concentrations has been practiced for a number of years. While the use of saliva has been generally reserved for the analysis of diagnostic and forensic/toxicology samples, attempts have been made to further enhance the value of saliva as an alternate matrix to those of plasma and serum. It is understood that saliva represents a handy tool for therapeutic drug monitoring (TDM) as it offers certain distinctive advantages. This scope of this review encompasses the following: (a) a comprehensive view of saliva as an alternate matrix for either plasma or serum to understand the pharmacokinetic/pharmacodynamic (PK/PD) characteristics; (b) an account of the factors contributing to the observed variability in salivary monitoring; (c) a tabular compilation of diverse case studies of xenobitoics belonging to different therapeutic classes with emphasis on assay methodology and applicable analytical/biopharmaceutical/pharmacokinetic findings; (d) relevant thoughts on assay procedures as they relate to salivary monitoring; and (e) some representative case studies highlighting the new thinking on the use of saliva outside of traditional TDM. Overall, based on the review, saliva represents a valuable TDM tool for a number of xenobiotics. While parent compound and phase I metabolite(s) for many xenobiotics have been generally quantifiable in saliva, phase II metabolites have not generally been detected in saliva. Therefore saliva samples could also be used to answer some specific PK/PD questions during the drug development process, if applicable. However, the development and validation of the assay in saliva needs to be carried out carefully with particular focus on proper sample collection, processing and storage to ensure the stability of the xenobiotics and with the same rigor as applied to plasma, serum and urine matrices. Copyright © 2008 John Wiley & Sons, Ltd.
- 24 September 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (1) , 3-25
Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives
The use of saliva for measuring xenobiotic concentrations has been practiced for a number of years. While the use of saliva has been generally reserved for the analysis of diagnostic and forensic/toxicology samples, attempts have been made to further enhance the value of saliva as an alternate matrix to those of plasma and serum. It is understood that saliva represents a handy tool for therapeutic drug monitoring (TDM) as it offers certain distinctive advantages. This scope of this review encompasses the following: (a) a comprehensive view of saliva as an alternate matrix for either plasma or serum to understand the pharmacokinetic/pharmacodynamic (PK/PD) characteristics; (b) an account of the factors contributing to the observed variability in salivary monitoring; (c) a tabular compilation of diverse case studies of xenobitoics belonging to different therapeutic classes with emphasis on assay methodology and applicable analytical/biopharmaceutical/pharmacokinetic findings; (d) relevant thoughts on assay procedures as they relate to salivary monitoring; and (e) some representative case studies highlighting the new thinking on the use of saliva outside of traditional TDM. Overall, based on the review, saliva represents a valuable TDM tool for a number of xenobiotics. While parent compound and phase I metabolite(s) for many xenobiotics have been generally quantifiable in saliva, phase II metabolites have not generally been detected in saliva. Therefore saliva samples could also be used to answer some specific PK/PD questions during the drug development process, if applicable. However, the development and validation of the assay in saliva needs to be carried out carefully with particular focus on proper sample collection, processing and storage to ensure the stability of the xenobiotics and with the same rigor as applied to plasma, serum and urine matrices. Copyright © 2008 John Wiley & Sons, Ltd.
- 17 September 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (2) , 222-223
Reversal in elution order in liquid chromatography—compilation of experimental observations
- 17 September 2008
- Published by Wiley in Biomedical Chromatography
- Vol. 23 (2) , 222-223
Reversal in elution order in liquid chromatography—compilation of experimental observations